Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1411548

Value of the lung immune prognostic index in patients with advanced small cell lung cancer treated with programmed death-ligand 1 and programmed death-1 inhibitors in the Chinese alpine region

Provisionally accepted
Meng Wang Meng Wang 1,2*Meiling Zhang Meiling Zhang 2Jingwei Hao Jingwei Hao 2Yunjiao Wu Yunjiao Wu 2
  • 1 Harbin Medical University, Harbin, China
  • 2 Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, China

The final, formatted version of the article will be published soon.

    Purpose: To assess the potential added value of the lung immune prognostic index (LIPI) in patients with small cell lung cancer (SCLC), treated with programmed death-ligand 1 (PD-L1)/ programmed death-1 (PD-1) inhibitors, who lived in the Chinese alpine region. Methods: 120 SCLC patients treated with PD-L1/PD-1 inhibitors were divided into three LIPI groups, from July 2018 to April 2021. Cox regression models were used to evaluate the prognostic effect of three LIPI groups on overall survival (OS) and progression-free survival (PFS). Logistic regression analysis was conducted to explore the association between immune-related adverse events (irAEs) and the pretreatment of neutrophil-to-lymphocyte ratio (dNLR), lactate dehydrogenase (LDH), and LIPI. Results: The median OS was 4.5, 6.3, and 10.0 months (p=0.001) and the median PFS was 2.5, 4.3, and 5.3 months (p=0.049) for Poor, Intermediate, and Good LIPI, respectively. The disease control rate (DCR) was also higher in the Good LIPI group (p=0.003). Moreover, multivariate analysis confirmed that worse LIPI was correlated with shorter OS and PFS. dNLR was associated with the onset of irAEs, not LIPI. Conclusion: The LIPI might be a promising predictive and prognostic biomarker in SCLC patients treated with PD-L1/PD-1 inhibitors in the Chinese Alpine region.

    Keywords: Lung immune prognostic index (LIPI), Small cell lung cancer (SCLC), programmed death-ligand 1 (PD-L1), Programmed death-1 (PD-1), Immune-related adverse events (irAEs), Prognostic factor

    Received: 03 Apr 2024; Accepted: 21 Jun 2024.

    Copyright: © 2024 Wang, Zhang, Hao and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Meng Wang, Harbin Medical University, Harbin, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.